当前位置: X-MOL 学术BMC Nephrol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic value of soluble ST2 and soluble LR11 on mortality and cardiovascular events in peritoneal dialysis patients.
BMC Nephrology ( IF 2.2 ) Pub Date : 2020-06-15 , DOI: 10.1186/s12882-020-01886-7
Yu Bum Choi 1 , Mi Jung Lee 1, 2 , Jung Tak Park 3 , Seung Hyeok Han 3 , Shin-Wook Kang 3 , Tae-Hyun Yoo 3 , Hyung Jong Kim 1
Affiliation  

Although the soluble form of suppression of tumorigenicity 2 (sST2) and soluble low-density lipoprotein receptor relative with 11 ligand-binding repeats (sLR11) have emerged as novel cardiovascular biomarkers in patients with cardiovascular disease, their prognostic value has not been fully investigated in peritoneal dialysis (PD) patients. We included 74 prevalent PD patients from a prospective cohort and measured serum sST2 and sLR11 concentrations by an enzyme-linked immunosorbent assay. The association of these biomarkers and all-cause mortality and major adverse cardiac and cerebrovascular events (MACCEs) was evaluated. During a follow-up of 38.5 months, all-cause deaths and MACCEs were observed in 13 (17.6%) patients and 23 (31.3%) patients. Multivariable Cox analyses demonstrated that greater sST2 was independently associated with higher risk of all-cause mortality (≥75.8 ng/mL; hazard ratio [HR] = 5.551; 95% confidence interval [CI] = 1.360–22.660) and MACCEs (≥72.5 ng/mL; HR = 4.609; 95% CI = 1.608–13.208). Furthermore, sST2 showed additive predictive value for mortality to the base model including traditional risk factors (net reclassification index = 0.598, P = 0.04). sLR11 was not significantly associated with all-cause mortality or MACCE. sST2, but not sLR11, indicated a significant prognostic value for all-cause mortality and cardiovascular events in PD patients. Further research is needed to validate emerging biomarkers in these populations.

中文翻译:

可溶性 ST2 和可溶性 LR11 对腹膜透析患者死亡率和心血管事件的预后价值。

尽管致瘤性抑制 2 (sST2) 的可溶性形式和具有 11 个配体结合重复序列 (sLR11) 的可溶性低密度脂蛋白受体已成为心血管疾病患者的新型心血管生物标志物,但它们的预后价值尚未在腹膜透析 (PD) 患者。我们纳入了来自前瞻性队列的 74 名流行 PD 患者,并通过酶联免疫吸附测定测量了血清 sST2 和 sLR11 浓度。评估了这些生物标志物与全因死亡率和主要不良心脑血管事件 (MACCE) 的关联。在 38.5 个月的随访期间,在 13 名(17.6%)患者和 23 名(31.3%)患者中观察到全因死亡和 MACCE。多变量 Cox 分析表明,较高的 sST2 与较高的全因死亡风险(≥75.8 ng/mL;风险比 [HR] = 5.551;95% 置信区间 [CI] = 1.360–22.660)和 MACCE(≥72.5)独立相关ng/mL;HR = 4.609;95% CI = 1.608–13.208)。此外,sST2 显示出对包括传统风险因素在内的基础模型的死亡率的附加预测价值(净重分类指数 = 0.598,P = 0.04)。sLR11 与全因死亡率或 MACCE 没有显着相关性。sST2,而不是 sLR11,对 PD 患者的全因死亡率和心血管事件具有重要的预后价值。需要进一步的研究来验证这些人群中新兴的生物标志物。人力资源 = 4.609;95% CI = 1.608–13.208)。此外,sST2 显示出对包括传统风险因素在内的基础模型的死亡率的附加预测价值(净重分类指数 = 0.598,P = 0.04)。sLR11 与全因死亡率或 MACCE 没有显着相关性。sST2,而不是 sLR11,对 PD 患者的全因死亡率和心血管事件具有重要的预后价值。需要进一步的研究来验证这些人群中新兴的生物标志物。人力资源 = 4.609;95% CI = 1.608–13.208)。此外,sST2 显示出对包括传统风险因素在内的基础模型的死亡率的附加预测价值(净重分类指数 = 0.598,P = 0.04)。sLR11 与全因死亡率或 MACCE 没有显着相关性。sST2,而不是 sLR11,对 PD 患者的全因死亡率和心血管事件具有重要的预后价值。需要进一步的研究来验证这些人群中新兴的生物标志物。表明对 PD 患者的全因死亡率和心血管事件具有重要的预后价值。需要进一步的研究来验证这些人群中新兴的生物标志物。表明对 PD 患者的全因死亡率和心血管事件具有重要的预后价值。需要进一步的研究来验证这些人群中新兴的生物标志物。
更新日期:2020-06-15
down
wechat
bug